2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1984

Implementation and Performance of an Objective Structured Clinical Examination (OSCE) in a National Certification Process of Trainees in Rheumatology. Two Years of Experience
Abstract Number: 2002

Implementation of a Collaborative Rheumatology and Physiatry Musculoskeletal Ultrasound Training Program
Abstract Number: 1519

Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Abstract Number: 1447

Implementing American College of Rheumatology (ACR) Quality Indicators for Rheumatoid Arthritis (RA) in the United Arab Emirates (UAE)
Abstract Number: 1810

Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety, and Wasted Health Care Resources
Abstract Number: 226

Improved Prediction of Hip Fracture Using the Health Assessment Questionnaire-Disability Index and FRAX^® in Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Study
Abstract Number: 2968

Improvement Following Total Knee Replacement (TKR) Surgery: Exploring Preoperative Symptoms and Change in Preoperative Symptoms
Abstract Number: 1996

Improvement in Basic Bone Health Knowledge Among VA Primary Care Practitioners during a Focused Musculoskeletal Mini-Residency
Abstract Number: 1348

Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record
Abstract Number: 1690

Improvement of Digital Ulcerative Disease in Patients with Systemic Sclerosis Is Associated with Better Functional Prognosis
Abstract Number: L5

Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE)
Abstract Number: 2397

Improvement of Fatigue in Patients with Rheumatoid Arthritis Treated with Biologics: Relationship with Sleep Disorders, Depression and Clinical Efficacy. a Prospective, Multicenter Study
Abstract Number: 2093

Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression
Abstract Number: 332

Improvement of the Stability of RNA Aptamers Against Interleukin-17A
Abstract Number: 2811

Improvements in Rheumatoid Arthritis Related Fatigue Are Driven By Reductions in Pain, Not Disease Activity – Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].